Silver Book

Silver Book Fact

Improvements in QoL from TAVR in SAS patients

Symptomatic aortic stenosis (SAS) patients who underwent transcatheter aortic valve replacement (TAVR) experienced quality of life (QoL) improvements from 5.3 at baseline (10 point scale with 10=best imaginable health state) to 6.7 at one year, and 7.4 at four years post procedure.

Kovac J, Schuler G, Gerckens U, et al. Four-Year Experience with CoreValve Transcatheter Heart Valve. EuroInterven. 2016; 12(8): 1039-46. https://www.pcronline.com/eurointervention/105th_issue/volume-12/number-8/169/four-year-experience-with-the-corevalve-transcatheter-heart-valve.html

Reference

Title
Four-Year Experience with CoreValve Transcatheter Heart Valve
Publication
EuroInterven
Publication Date
2016
Authors
Kovac J, Schuler G, Gerckens U, et al
Volume & Issue
Volume 12, Issue 8
Pages
1039-46
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Publications

Aortic Stenosis Fact Sheet

 https://www.silverbook.org/wp-content/uploads/2017/10/AS-FS-cover.png Thumbnail

Related Facts

  • Cost-effectiveness of TAVR in sSAS patients
    Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY…  
  • Cost-effectiveness of SAVR
    The cost-effectiveness ratio for surgical aortic valve replacement (SAVR), compared to no surgery, was estimated at $13,528 per quality-adjusted life year (QALY) (~$17,225 in 2017 dollars).  
  • Survival Rates of SAS Patients with and without SAVR
    Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with…  
  • Disease specific status and generic health status improvements from TAVR and SAVR
    Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in intermediate risk symptomatic aortic stenosis (SAS) patients were associated with significant improvements in disease specific status (16 to…  
  • TAVR improves quality of life in SAS patients